Skip to main content
. Author manuscript; available in PMC: 2022 Sep 2.
Published in final edited form as: J Virol Methods. 2021 Aug 9;297:114262. doi: 10.1016/j.jviromet.2021.114262

Table 2.

WPV1 inactivation by commercial nucleic acid extraction buffers.

Extraction Buffer Sample: Buffer Ratio Additional Components Added Incubation Time Viral Titer Post-Treatment (log CCID50/ 0.1 mL)
PBS (control) 1:4 None 30 min 8.6 ± 0.1
Trizol LS 1:3 None 30 min Below LOD
Viral RNA Buffer 1:3 0.5 % β-mercaptoethanol 30 min Below LOD
Buffer AVL 1:4 None 30 min 3.6 ± 0.4
Buffer AVL + Ethanol 1:4 Ethanol (44 % final) 30 min Below LOD
UNEX 1:1 None 30 min 1.4 ± 0.1
UNEX + Ethanol 1:1 Ethanol (50 % final) 30 min Below LOD
MagMAX Lysis/Binding Concentrate 1:2 None 30 min Below LOD
High Pure Binding Buffer 1:2 None 30 min 7.8 ± 0.3
High Pure Binding Buffer with Proteinase K 1:2 Proteinase K 30 min Below LOD

WPV1 isolate was incubated with extraction buffers Buffer AVL, Trizol and UNEX, Viral RNA Buffer, MagMAX Lysis/Binding Concentrate, or High Pure Binding Buffer with or without ethanol and reducing agents, for 30 min at room temperature. Samples were concentrated and resulting viral titers determined by CCID50 assay. LOD, Limit of detection (0.5 log10 CCID50/0.1 mL).